CN110403012A - 一种鱼针草内酯用于制备抑制胃幽门螺旋杆菌的蛋白质合成的组合物的用途 - Google Patents
一种鱼针草内酯用于制备抑制胃幽门螺旋杆菌的蛋白质合成的组合物的用途 Download PDFInfo
- Publication number
- CN110403012A CN110403012A CN201810393419.6A CN201810393419A CN110403012A CN 110403012 A CN110403012 A CN 110403012A CN 201810393419 A CN201810393419 A CN 201810393419A CN 110403012 A CN110403012 A CN 110403012A
- Authority
- CN
- China
- Prior art keywords
- helicobacter pylori
- purposes
- milligrams
- needle grass
- stomach
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000251468 Actinopterygii Species 0.000 title claims abstract description 41
- 241000590002 Helicobacter pylori Species 0.000 title claims abstract description 41
- 229940037467 helicobacter pylori Drugs 0.000 title claims abstract description 41
- 150000002596 lactones Chemical class 0.000 title claims abstract description 36
- 210000002784 stomach Anatomy 0.000 title claims abstract description 26
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 14
- 239000000203 mixture Substances 0.000 title claims abstract description 12
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 9
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 9
- 241000270955 Achnatherum calamagrostis Species 0.000 title 1
- 241001523383 Achnatherum Species 0.000 claims abstract description 40
- 230000014616 translation Effects 0.000 claims abstract description 14
- 206010019375 Helicobacter infections Diseases 0.000 claims abstract description 13
- 238000001243 protein synthesis Methods 0.000 claims abstract description 12
- 230000000694 effects Effects 0.000 claims abstract description 10
- 210000003705 ribosome Anatomy 0.000 claims abstract description 10
- 235000013336 milk Nutrition 0.000 claims description 17
- 239000008267 milk Substances 0.000 claims description 17
- 210000004080 milk Anatomy 0.000 claims description 17
- 235000013618 yogurt Nutrition 0.000 claims description 11
- 241000894006 Bacteria Species 0.000 claims description 9
- 206010048723 Multiple-drug resistance Diseases 0.000 claims description 9
- 210000001187 pylorus Anatomy 0.000 claims description 9
- 244000068988 Glycine max Species 0.000 claims description 7
- 235000010469 Glycine max Nutrition 0.000 claims description 7
- 235000013351 cheese Nutrition 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 235000009508 confectionery Nutrition 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 241001674329 Helicobacter pylori 26695 Species 0.000 claims description 5
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 4
- 235000015203 fruit juice Nutrition 0.000 claims description 4
- 235000015243 ice cream Nutrition 0.000 claims description 4
- 235000015110 jellies Nutrition 0.000 claims description 4
- 235000010603 pastilles Nutrition 0.000 claims description 4
- 239000000047 product Substances 0.000 claims description 4
- 235000011496 sports drink Nutrition 0.000 claims description 4
- 235000008452 baby food Nutrition 0.000 claims description 3
- 235000013361 beverage Nutrition 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 235000013365 dairy product Nutrition 0.000 claims description 3
- 235000021185 dessert Nutrition 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 3
- 238000007710 freezing Methods 0.000 claims description 3
- 235000012055 fruits and vegetables Nutrition 0.000 claims description 3
- 235000001497 healthy food Nutrition 0.000 claims description 3
- 239000008274 jelly Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 241000186660 Lactobacillus Species 0.000 claims description 2
- 229940112822 chewing gum Drugs 0.000 claims description 2
- 235000015218 chewing gum Nutrition 0.000 claims description 2
- 239000002131 composite material Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 229940039696 lactobacillus Drugs 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 1
- 235000012054 meals Nutrition 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000013589 supplement Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 abstract description 5
- 239000003814 drug Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 230000003115 biocidal effect Effects 0.000 description 8
- 229940126409 proton pump inhibitor Drugs 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000000612 proton pump inhibitor Substances 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 150000001621 bismuth Chemical class 0.000 description 5
- 235000015872 dietary supplement Nutrition 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 229930027917 kanamycin Natural products 0.000 description 4
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229960003276 erythromycin Drugs 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- KTYZKXFERQUCPX-XGKXUXTPSA-N 3,7,11,15(17)-cembratetraene-16,2:19,6-diolide Chemical compound C([C@@H]1C(=C)C(=O)O[C@H]1/C=C(C)/C1)CC(/C)=C/CCC2=C[C@@H]1OC2=O KTYZKXFERQUCPX-XGKXUXTPSA-N 0.000 description 2
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 2
- 240000000782 Anisomeles indica Species 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 206010015856 Extrasystoles Diseases 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 229960003022 amoxicillin Drugs 0.000 description 2
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 208000023652 chronic gastritis Diseases 0.000 description 2
- 229960002626 clarithromycin Drugs 0.000 description 2
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 229960001398 flurithromycin Drugs 0.000 description 2
- XOEUHCONYHZURQ-HNUBZJOYSA-N flurithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@@](C)(F)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 XOEUHCONYHZURQ-HNUBZJOYSA-N 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- -1 glidant (glidants) Substances 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229960000282 metronidazole Drugs 0.000 description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 2
- 229960000381 omeprazole Drugs 0.000 description 2
- KTYZKXFERQUCPX-KURKYZTESA-N ovatodiolide Natural products CC1=CCCC2=C[C@@H](CC(C)=C[C@@H]3OC(=O)C(=C)[C@H]3CC1)OC2=O KTYZKXFERQUCPX-KURKYZTESA-N 0.000 description 2
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 206010060976 Bacillus infection Diseases 0.000 description 1
- 101100297347 Caenorhabditis elegans pgl-3 gene Proteins 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 238000003718 Dual-Luciferase Reporter Assay System Methods 0.000 description 1
- 239000004129 EU approved improving agent Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 240000002129 Malva sylvestris Species 0.000 description 1
- 235000006770 Malva sylvestris Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 241000242678 Schistosoma Species 0.000 description 1
- ZNRPKTMOAASBNJ-UHFFFAOYSA-N [Bi+5] Chemical compound [Bi+5] ZNRPKTMOAASBNJ-UHFFFAOYSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- IYNWNKYVHCVUCJ-UHFFFAOYSA-N bismuth Chemical compound [Bi].[Bi] IYNWNKYVHCVUCJ-UHFFFAOYSA-N 0.000 description 1
- JDIBGQFKXXXXPN-UHFFFAOYSA-N bismuth(3+) Chemical compound [Bi+3] JDIBGQFKXXXXPN-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 235000021113 dry cheese Nutrition 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019985 fermented beverage Nutrition 0.000 description 1
- 235000021001 fermented dairy product Nutrition 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229960003174 lansoprazole Drugs 0.000 description 1
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000001937 non-anti-biotic effect Effects 0.000 description 1
- 210000001711 oxyntic cell Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 239000012744 reinforcing agent Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000021262 sour milk Nutrition 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/48—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Botany (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Fodder In General (AREA)
Abstract
本发明涉及一种鱼针草内酯用于制备抑制胃幽门螺旋杆菌的蛋白质合成的组合物的用途，其中该鱼针草内酯通过抑制胃幽门螺旋杆菌的30S核醣体RpsB的表达，进而抑制其蛋白质合成，从而达到抑制胃幽门杆菌的功效。
Description
【技术领域】
本发明涉及鱼针草内酯的用途，特别涉及抑制抗药性胃幽门螺旋杆菌的用途。
【背景技术】
幽门螺旋杆菌属于微需氧的革兰氏阴性菌，而人类是幽门螺旋杆菌的唯一宿主，其感染在患者的胃和十二指肠的黏膜层上，是最常见的细菌感染之一，其中流行病学研究发现幽门螺旋杆菌与胃癌有高达70％相关性(Marshall B.2002.)。许多研究指出，幽门螺旋杆菌感染会造成肠胃疾病，例如:胃溃疡(gastric ulcer)、慢性胃炎(chronicgastritis)甚至胃腺癌(gastric adenocarcinoma)(Marshall BJ,Warren JR.1984.,NIHConsensus Conference 1994,Schistosomes 1994.)。因此，若能根除幽门螺旋杆菌即可降低罹患胃癌的机率。
目前根除幽门螺旋杆菌的主要方法为三联疗法(triple therapy)，另外还有单一疗法(mono therapy)、二联疗法(dual therapy)及四联疗法(quadruple therapy)。单一疗法使用单一药剂治疗，如抗生素、铋盐等。二联疗法使用铋盐或质子帮浦抑制剂(protonpump inhibitor,PPI)加上一种抗生素，需时2周。三联疗法使用铋盐或质子帮浦抑制剂加上两种抗生素，需时1-2周。四联疗法使用铋盐、质子帮浦抑制剂加上两种抗生素，需时1周，但是药剂使用复杂，彼此之间容易发生交互作用，以及产生新的副作用等。
目前市面上常用于根除幽门螺旋杆菌的抗生素包括克拉霉素(clarithromycin)、阿莫西林(amoxicillin)、氟红霉素(flurithromycin)、四环素(tetracycline)以及甲硝唑(metronidazole)等。质子帮浦抑制剂对幽门螺旋杆菌的作用主要是抑制胃酸的形成和静菌作用，常用的质子帮浦抑制剂有奥美拉唑(omeprazole)和兰索拉唑(lansporazole)等。铋盐(bismuth)具有杀死幽门螺旋杆菌和保护胃壁细胞的作用，常用的铋盐有bismuth(III)和bismuth(V)等。抗生素是目前最有效的根除幽门螺旋杆菌感染的药物，然而，抗生素的不当使用所带来的抗药性问题，成为幽门螺旋杆菌根除失败的主要原因。为了解决抗药性导致治疗困难的问题，近几年开始研究从天然药草中萃取可以有效治疗幽门螺旋杆菌的化合物(Lee SY,Shin YW,Hahm KB.2008.)，发展出一种非抗生素的治疗方法。
鱼针草(Anisomeles indica，又称金剑草)为唇形科多年生草本植物，生长于亚热带地区，常用于治疗肠胃炎和免疫系统不全等相关疾病，先前发现其萃取物能有效抑制发炎反应以及肿瘤增生(Rao YK,Fang SH,Hsieh SC,Yeh TH,Tzeng YM.2009.,Hsieh SC,Fang SH,Rao YK,Tzeng YM.2008.)。此外，有文献(Lien HM,Wang CY,Chang HY,Huang CL,Peng MT,Sing YT,Chen CC,Lai CH.2013.,Rao YK,Lien HM,Lin YH,Hsu YM,Yeh CT,ChenCC,Lai CH,Tzeng YM.2012.)揭示鱼针草萃取物具有抑制幽门螺旋杆菌的功效，由于其抑制机制以及是否具有抑制抗药性幽门螺旋杆菌的功效仍不清楚，因此需要提供鱼针草抑制幽门螺旋杆菌的作用机制以解决本领域存在的问题。
【发明内容】
鉴于此，本发明提供一种鱼针草内酯(ovatodiolide)用于抑制胃幽门杆菌的蛋白质合成的用途。
为达到上述目的，本发明提供一种鱼针草内酯用于制备抑制胃幽门螺旋杆菌的蛋白质合成的组合物的用途，其中该鱼针草内酯通过抑制蛋白质合成从而达到抑制胃幽门杆菌的功效。
其中，胃幽门螺旋杆菌是指多重抗药性胃幽门螺旋杆菌或幽门杆菌标准菌株，且多重抗药性胃幽门螺旋杆菌是指HP v633或HP v1354，幽门杆菌标准菌株为H.pylori26695。
其中，该蛋白质合成是通过30S核醣体RpsB的作用完成的。
其中，该鱼针草内酯抑制胃幽门杆菌的有效剂量为16毫克～1642毫克；优选剂量为82毫克～821毫克；最优选剂量为164毫克～329毫克。
其中，该组合物可进一步包括药学上可接受的载剂、赋形剂、稀释剂；剂型选自溶液、悬浮液、乳剂、粉末、锭剂、丸剂、糖浆、口含锭、片剂、咀嚼胶、浓浆、和胶囊。
其中，该组合物可进一步制成流体乳制品、浓缩牛奶、酸奶、酸乳、冷冻优格、乳杆菌发酵饮料、奶粉、冰淇淋、奶酪、干酪、豆浆、发酵豆浆、蔬果汁、果汁、运动饮料、甜点、果冻、糖果、婴儿食品、健康食品、动物饲料、中草药组合物、膳食补充品。
【附图说明】
图1为鱼针草抑制幽门螺旋杆菌的蛋白质合成的图；
图2为鱼针草抑制幽门螺旋杆菌的核醣体组装的图。
【具体实施方式】
本说明书中所述的所有技术性及科学术语，除非另有定义，均为本领域技术人员可共同理解的含义。
本说明书术语“载剂(carrier)”、“赋形剂(vehicle)”，是指不具毒性的化合物或药剂，其具有协助细胞或组织吸收药物的功能。
前述载剂或赋形剂可以为芳香剂(aromatics)、缓冲剂、黏着剂(binders)、着色剂(colorants)、崩解剂(disintegrants)、稀释剂、乳化剂(emulsifiers)、增量剂(extenders)、气味改善剂(flavor-improving agents)、胶凝剂(gellants)、助流剂(glidants)、防腐剂、皮肤渗透促进剂(skin-penetration enhancers)、助溶剂(solubilizers)、安定剂(stabilizers)、悬浮剂(suspending agents)、甜味剂(sweeteners)、张度剂(tonicity agents)、黏度增强剂(viscosity-increasing agents)或上述任意组合。
本说明书术语“有效剂量(effective amount)”或“治疗(therapeutically)有效剂量”，是指相关化合物或药物的足够剂量，其可使服用者服药后减轻一种或多种疾病症状或生理状况；其结果为降低和/或缓和迹象(sign)、症状(symptom)、或病因，或有意图地改变其他生理系统。举例而言，治疗的「有效剂量」包括本发明提供的化合物可在临床上显著降低疾病症状的剂量。适当的有效量的有效值取决于普通药学技术，例如药物增量方法(dose escalation methods)。
本发明所使用的组合物，可进一步添加一种可食性材料，以制备一种食品产品或保健产品。其中该可食性材料包含，但不限于：水(water)、流体乳制品(fluid milkproducts)、牛奶(milk)、浓缩牛奶(concentrated milk)；发酵乳制品(fermented milk)，诸如酸奶(yogurt)、酸乳(sour milk)、冷冻优格(frozen yogurt)、乳杆菌发酵饮料(lactic acid bacteria-fermented beverages)；奶粉(milk powder)；冰淇淋(icecream)；奶酪(cream cheeses)；干酪(dry cheeses)；豆奶(soybean milk)；发酵豆奶(fermented soybean milk)；蔬果汁(vegetable-fruit juices)；果汁(juices)；运动饮料(sports drinks)；甜点(confectionery)；果冻(jellys)；糖果(candies)；婴儿食品(infant formulas)；健康食品(health foods)；动物饲料(animal feeds)；中草药材(Chinese herbals)；膳食补充品(dietary supplements)等。
本发明所使用的前述组合物可为膳食补充品，可以通过下列方式给予服用者：与合适的可饮用液体混合，例如水、酸奶酪、牛奶或果汁；或可与固体或液体食品进行混合。在本说明书中，膳食补充品的形式可为锭剂、丸剂、胶囊、糖锭(lozenge)、颗粒、粉剂、悬浮剂、小药囊、软锭剂、糖果、棒、糖浆及相应的投与形式，通常以单位剂量的形式，并通过膳食补充品的常规制备方法来制造。
以下实施例仅作为例示，剂量可依据需要而作出改变，而不限于所使用的化合物的活性、治疗疾病或生理状态、给药方式、个体需求、疾病严重性以及医生的判断。
实施例1：鱼针草内酯抗幽门螺旋杆菌的最小抑菌浓度
用不同浓度的鱼针草内酯(ovatodiolide)纸锭，分别与幽门螺旋杆菌培养两天，通过琼酯孔洞扩散法(agar-well diffusion)测定鱼针草内酯抑制幽门螺旋杆菌的最小浓度，由此分析鱼针草内酯抑制幽门螺旋杆菌标准菌株(H.pylori 26695)生长的最低浓度。表一为抑制幽门螺旋杆菌标准菌株(H.pylori 26695)的最小抑菌浓度，由实验结果可知10μM及20μM的鱼针草内酯均有抑制环，而其抑制环直径分别为10±0.5mm和19±0mm，这证明鱼针草内酯抑制幽门螺旋杆菌的最低浓度为10μM。
表一、抑制幽门螺旋杆菌标准菌株(H.pylori 26695)的最小抑制浓度
实施例2：抗幽门螺旋杆菌标准菌株及其多重抗药性菌株的最小杀菌浓度
利用系列稀释的方式配制不同浓度的鱼针草内酯，并分别与从实验室分离的幽门螺旋杆菌标准菌株和多重抗药性幽门螺旋杆菌(v633,v1354)培养六小时，再以涂布平板法(spread plate method)观察并分析菌落生长数目，分析可完全杀死幽门螺旋杆菌标准菌株及多重抗药性菌株的鱼针草内酯的最低杀菌浓度。由表二结果可知，鱼针草内酯对幽门螺旋杆菌标准菌株的最小杀菌浓度为200μM，而对多重抗药性菌株v633和v1354的最小杀菌浓度均为100μM。
表二、鱼针草内酯对多重抗药螺旋杆菌的最小杀菌浓度
实施例3：鱼针草内酯抑制幽门螺旋杆菌的蛋白质合成
由于鱼针草内酯的结构与抗生素中抑制蛋白质生成的药物相似，为了解鱼针草内酯抑制幽门螺旋杆菌的机制是否与蛋白质合成有关，利用体外转录-转译系统(in vitroTranscription/Translation system)，将鱼针草内酯与大肠杆菌萃取物(E.coli S30)作用10分钟后，加入带有荧光素酶(luciferase)的pGL3进行转录和转译反应2小时，最后利用双荧光素酶报告基因检测系统(Dual-Luciferase Reporter Assay System)，将反应完成的样品加入荧光素(luciferin)使其呈色，再通过微孔板光度计(microplateluminometer)测定吸光值，即可得知鱼针草内酯是否会抑制蛋白质合成。
其中，以抑制30S亚单元(subunit)的卡那霉素(kanamycin)和抑制50S亚单元的红霉素(erythromycin)作为对照组。图1结果显示10μM的鱼针草内酯对蛋白质合成的抑制为50％以上，而1μM的卡那霉素和红霉素抑制蛋白质合成的能力为75％以上，由此可知鱼针草内酯的药物机制与抑制蛋白质合成有关。
实施例4：鱼针草内酯抗幽门螺旋杆菌的核醣体组装
在另一实施例中，蛋白质转译的过程分三个步骤，分别为核糖体起始(Initiation)、延长(Elongation)、终止(Termination)，而为了进一步分析鱼针草内酯是否作用于核糖体导致蛋白质合成无法顺利进行，以蛋白质印迹分析法(western blotanalysis)测定核醣体30S亚单元中的RpsB蛋白质含量，将幽门螺旋杆菌与不同浓度的鱼针草内酯一起培养6小时并萃取总细胞溶解产物(total cell lysates)。再利用10％SDS-PAGE分离总细胞溶解产物，并用PVDF膜转渍蛋白质，将RpsB抗体与蛋白质进行杂合(hybridization)，再用抗兔(anti-rabbit)抗体侦测RpsB抗体，最后加入呈色剂，利用仪器Azure C400Biosystems观察结果。
图2为利用蛋白质印迹分析法分析核醣体30S亚单元的RpsB表达量，其中卡那霉素(400μM)和红霉素(400μM)为对照组，结果显示RpsB蛋白质与鱼针草内酯作用后，其蛋白质表达量明显下降，这与对照组结果相似。
鱼针草内酯在体外实验对于细菌抑制的有效浓度为10μM～1mM，鱼针草内酯分子量为328.4，假设65公斤的成人体内约有血液5公升，由此推算出人体每日有效剂量为16毫克～1642毫克；优选药物浓度为50μM～500μM，则推算出每日优选剂量为82毫克～821毫克；最优选浓度为100μM～200μM，则推算出最优选剂量为每日164毫克～329毫克。
综上所述，本发明的鱼针草内酯通过抑制胃幽门螺旋杆菌的30S核醣体RpsB的表达，从而抑制蛋白质合成，并且进一步有效抑制幽门螺旋杆菌标准菌株及多重抗药菌株的生长，该鱼针草内酯抑制胃幽门杆菌的有效剂量为16毫克～1642毫克；优选剂量为82毫克～821毫克；最优选剂量为164毫克～329毫克。
以上所述的实施例仅用于说明本发明的技术思想及特点，其目的在于使本领域技术人员能够了解本发明的内容并予以实施，而不能因此限定本发明的专利范围，即，凡是按照本发明所揭示的精神所作出的等同变化或修改，仍应涵盖在本发明的专利范围内。
Claims (10)
1.一种鱼针草内酯用于制备抑制胃幽门螺旋杆菌的蛋白质合成的组合物的用途，其特征在于，所述鱼针草内酯通过抑制胃幽门螺旋杆菌的蛋白质合成而达到抑制胃幽门杆菌的功效。
2.如权利要求1所述的用途，其特征在于，所述胃幽门螺旋杆菌为多重抗药性胃幽门螺旋杆菌或幽门杆菌标准菌株。
3.如权利要求2所述的用途，其特征在于，所述多重抗药性胃幽门螺旋杆菌为HP v633或HP v1354，所述幽门杆菌标准菌株为H.pylori 26695。
4.如权利要求1所述的用途，其特征在于，所述蛋白质合成是通过30S核醣体RpsB的作用完成的。
5.如权利要求1所述的用途，其特征在于，所述鱼针草内酯抑制所述胃幽门杆菌的有效剂量为16毫克～1642毫克。
6.如权利要求1所述的用途，其特征在于，所述鱼针草内酯抑制所述胃幽门杆菌的剂量为82毫克～821毫克。
7.如权利要求1所述的用途，其特征在于，所述鱼针草内酯抑制所述胃幽门杆菌的剂量为164毫克～329毫克。
8.如权利要求1所述的用途，其特征在于，所述组合物包括药学上可接受的载剂、赋形剂、稀释剂。
9.如权利要求1所述的用途，其特征在于，所述组合物的剂型选自溶液、悬浮液、乳剂、粉末、锭剂、丸剂、糖浆、口含锭、片剂、咀嚼胶、浓浆和胶囊。
10.如权利要求1所述的用途，其特征在于，所述组合物制成流体乳制品、浓缩牛奶、酸奶、酸乳、冷冻优格、乳杆菌发酵饮料、奶粉、冰淇淋、奶酪、干酪、豆浆、发酵豆浆、蔬果汁、果汁、运动饮料、甜点、果冻、糖果、婴儿食品、健康食品、动物饲料、中草药组合物、膳食补充品。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810393419.6A CN110403012A (zh) | 2018-04-27 | 2018-04-27 | 一种鱼针草内酯用于制备抑制胃幽门螺旋杆菌的蛋白质合成的组合物的用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810393419.6A CN110403012A (zh) | 2018-04-27 | 2018-04-27 | 一种鱼针草内酯用于制备抑制胃幽门螺旋杆菌的蛋白质合成的组合物的用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110403012A true CN110403012A (zh) | 2019-11-05 |
Family
ID=68346810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810393419.6A Pending CN110403012A (zh) | 2018-04-27 | 2018-04-27 | 一种鱼针草内酯用于制备抑制胃幽门螺旋杆菌的蛋白质合成的组合物的用途 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110403012A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021208080A1 (zh) * | 2020-04-17 | 2021-10-21 | 毓维生物科技股份有限公司 | 鱼针草内酯抗新型冠状病毒的用途 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1331250A (zh) * | 2000-04-14 | 2002-01-16 | 株式会社源 | 对幽门螺杆菌定居具有抑制活性的糖蛋白 |
| TW201200146A (en) * | 2010-06-24 | 2012-01-01 | Yushen Biotechnology & Amp Medical Co Ltd | Composition containing ovatodiolide and application thereof to suppressing helicobacter pylori |
| TW201233393A (en) * | 2011-02-01 | 2012-08-16 | Univ Chaoyang Technology | A pharmaceutical composition for inhibition of helicobacter pylori growth and helicobacter pylori-induced inflammation in human gastric epithelial cells |
| CN102824417A (zh) * | 2011-09-26 | 2012-12-19 | 王子厚 | 治疗幽门螺旋杆菌相关疾病的新方法 |
| TW201313243A (zh) * | 2011-09-19 | 2013-04-01 | Yushen Biotechnology & Medical Co Ltd | 魚針草內酯或魚針草萃取物用於製造抑制細菌引起之發炎反應之醫藥組成物的用途 |
-
2018
- 2018-04-27 CN CN201810393419.6A patent/CN110403012A/zh active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1331250A (zh) * | 2000-04-14 | 2002-01-16 | 株式会社源 | 对幽门螺杆菌定居具有抑制活性的糖蛋白 |
| TW201200146A (en) * | 2010-06-24 | 2012-01-01 | Yushen Biotechnology & Amp Medical Co Ltd | Composition containing ovatodiolide and application thereof to suppressing helicobacter pylori |
| TW201233393A (en) * | 2011-02-01 | 2012-08-16 | Univ Chaoyang Technology | A pharmaceutical composition for inhibition of helicobacter pylori growth and helicobacter pylori-induced inflammation in human gastric epithelial cells |
| TW201313243A (zh) * | 2011-09-19 | 2013-04-01 | Yushen Biotechnology & Medical Co Ltd | 魚針草內酯或魚針草萃取物用於製造抑制細菌引起之發炎反應之醫藥組成物的用途 |
| CN102824417A (zh) * | 2011-09-26 | 2012-12-19 | 王子厚 | 治疗幽门螺旋杆菌相关疾病的新方法 |
Non-Patent Citations (2)
| Title |
|---|
| LIEN HM,等: "Bioevaluation of Anisomeles indica extracts and their inhibitory effects on Helicobacter pylori-mediated inflammation", 《JOURNALOFETHNOPHARMACOLOGY》 * |
| RAO, YK，等: "Antibacterial activities of Anisomeles indica constituents and their inhibition effect on Helicobacter pylori-induced inflammation in human gastric epithelial cells", 《FOOD CHEMISTRY》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021208080A1 (zh) * | 2020-04-17 | 2021-10-21 | 毓维生物科技股份有限公司 | 鱼针草内酯抗新型冠状病毒的用途 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1312374B1 (en) | Primrose seed extracts as sugar absorption inhibitors and process for producing the same | |
| CN108289485A (zh) | 甜菊醇糖苷共混物、组合物和方法 | |
| TWI787950B (zh) | 用於預防、緩解或治療冠狀病毒感染的包括杜英萃取物作為活性成分之藥物組成物以及食品組成物 | |
| CN110447799A (zh) | 一种用于改善肠道菌群的复合固体植物饮料及其制备方法 | |
| WO2020118576A1 (zh) | 胚芽乳酸杆菌twk10在制备抗运动后发炎或降体脂组合物的用途 | |
| KR20060111561A (ko) | 해조 추출물 및 그것을 함유하는 당질 가수 분해 효소 저해제 | |
| CN110522034A (zh) | 一种含有黑大麦乳杆菌发酵物的功能性食品及应用 | |
| WO2010131910A2 (ko) | 발효차를 함유하는 혈액 순환 개선용 조성물 및 이를 포함하는 약제학적 및 건강 식품 조성물 | |
| WO2005074961A1 (ja) | 体脂肪調整剤 | |
| EP2147677B1 (en) | Eradicating agent for helicobacter pylori | |
| CN110403012A (zh) | 一种鱼针草内酯用于制备抑制胃幽门螺旋杆菌的蛋白质合成的组合物的用途 | |
| CN101297820A (zh) | 屎链球菌功能信号分子制剂及其降脂减肥制品 | |
| KR20200070081A (ko) | 충치 억제 활성을 갖는 락토바실러스 살리바리우스를 포함하는 조성물 | |
| CN112472733B (zh) | 一种促进钙口服吸收的葛花提取物 | |
| KR101237215B1 (ko) | 장염 예방 또는 치료용 약학 조성물 | |
| KR101047796B1 (ko) | 인슐린 저항성 개선 효능을 갖는 냉초 추출물 및 이를 유효성분으로 함유하는 제품 | |
| TW201945017A (zh) | 一種魚針草內酯用於製備抑制細菌蛋白質合成組合物之用途 | |
| US20190358198A1 (en) | Use of ovatodiolide for preparing a composition for inhibiting protein synthesis of gastric helicobacter pypori | |
| CN110169452A (zh) | 一种含变性淀粉的助消化酸奶及其制备方法 | |
| KR20200070080A (ko) | 충치 억제 활성을 갖는 락토바실러스 루테리 mg505 를 포함하는 조성물 | |
| TWI817632B (zh) | 益生菌加中草藥的組合物及其用途 | |
| CN115094001B (zh) | 肠膜明串珠菌及其在制备抑制幽门螺杆菌的药物中的应用 | |
| CN115006432B (zh) | 一种抗幽门螺旋杆菌的益生菌组合物 | |
| JP7469778B2 (ja) | エクオールを有効成分として含む腸内細菌に対する抗菌剤 | |
| EP4326281A1 (en) | Nutritional supplement and uses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20191105 |